JP2019520392A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520392A5
JP2019520392A5 JP2019500316A JP2019500316A JP2019520392A5 JP 2019520392 A5 JP2019520392 A5 JP 2019520392A5 JP 2019500316 A JP2019500316 A JP 2019500316A JP 2019500316 A JP2019500316 A JP 2019500316A JP 2019520392 A5 JP2019520392 A5 JP 2019520392A5
Authority
JP
Japan
Prior art keywords
composition
administration
enzyme
cgl
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019500316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/040897 external-priority patent/WO2018009663A1/en
Publication of JP2019520392A publication Critical patent/JP2019520392A/ja
Publication of JP2019520392A5 publication Critical patent/JP2019520392A5/ja
Ceased legal-status Critical Current

Links

JP2019500316A 2016-07-06 2017-07-06 ヒト酵素媒介性シスチン枯渇 Ceased JP2019520392A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359018P 2016-07-06 2016-07-06
US62/359,018 2016-07-06
PCT/US2017/040897 WO2018009663A1 (en) 2016-07-06 2017-07-06 Human-enzyme mediated depletion of cystine for treating patients with cystinuria

Publications (2)

Publication Number Publication Date
JP2019520392A JP2019520392A (ja) 2019-07-18
JP2019520392A5 true JP2019520392A5 (https=) 2020-07-02

Family

ID=60892921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019500316A Ceased JP2019520392A (ja) 2016-07-06 2017-07-06 ヒト酵素媒介性シスチン枯渇

Country Status (11)

Country Link
US (1) US20180008681A1 (https=)
EP (1) EP3481425A4 (https=)
JP (1) JP2019520392A (https=)
KR (1) KR20190026813A (https=)
CN (1) CN109562178A (https=)
AU (1) AU2017291842A1 (https=)
BR (1) BR112019000215A2 (https=)
CA (1) CA3028771A1 (https=)
IL (1) IL263997A (https=)
MX (1) MX383505B (https=)
WO (1) WO2018009663A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2531597B1 (en) 2010-02-04 2021-01-06 AEMase, Inc. Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
KR102244750B1 (ko) 2013-08-29 2021-04-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 치료적 목적을 위한 조작된 영장류 l-메티오니나제
KR102269209B1 (ko) 2013-08-29 2021-06-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항신생물제로서 조작된 영장류 시스틴/시스테인 분해 효소
US10865403B2 (en) 2017-05-12 2020-12-15 Board Of Regents, The University Of Texas System Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
KR102680776B1 (ko) 2017-05-12 2024-07-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 고호모시스테인혈증 및 호모시스틴뇨증 환자를 치료하기 위한 인간-효소 매개된 호모시스테인의 고갈
SG11202104205XA (en) 2018-10-26 2021-05-28 Univ Texas Engineered primate cystine/cysteine degrading enzymes for therapeutic uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
US20060275279A1 (en) * 2005-06-06 2006-12-07 Rozzell J D Methods for dissolving cystine stones and reducing cystine in urine
EP1749822B1 (en) * 2005-08-05 2008-10-15 Hybrigenics S.A. Novel cysteine protease inhibitors and their therapeutic applications
HUE042177T2 (hu) * 2009-12-01 2019-06-28 Translate Bio Inc Szteroidszármazék mRNS szállítására humán genetikai betegségekben
KR102244750B1 (ko) 2013-08-29 2021-04-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 치료적 목적을 위한 조작된 영장류 l-메티오니나제
KR102269209B1 (ko) * 2013-08-29 2021-06-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항신생물제로서 조작된 영장류 시스틴/시스테인 분해 효소

Similar Documents

Publication Publication Date Title
JP2019520392A5 (https=)
JP2019194251A5 (https=)
JP2020203894A5 (https=)
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
ES2690147T3 (es) Apelina pegilada y usos de la misma
JP2016533753A5 (https=)
JP2014526441A5 (https=)
JP2011526303A5 (https=)
JP2008529558A5 (https=)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2008530245A5 (https=)
JP2015517489A5 (https=)
JP2013515057A5 (https=)
JP2016539946A5 (https=)
JP2010500399A5 (https=)
JP2010520758A5 (https=)
FI4004022T3 (fi) Materiaaleja ja menetelmiä friedreichin ataksian hoitamiseksi
CN1655675A (zh) 利用三叶肽的联合治疗
JP2020530282A5 (https=)
JP5981141B2 (ja) 多臓器不全症候群(mods)の予防および/または処置のためのインターロイキン−22の使用
JP2020519278A5 (https=)
RU2009104749A (ru) Рекомбинантные белки, подобные человеческому интреферону
JP2021521777A5 (https=)
JP2018509423A5 (https=)
JP2018532763A5 (https=)